271. 強直性脊椎炎
[臨床試験数:531,薬物数:343(DrugBank:66),標的遺伝子数:41,標的パスウェイ数:141

Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
42 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-002061-54-IT
(EUCTR)
13/10/201615/11/2018Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases.Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases.Evaluation of immunogenicity and clinical response - Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) Rheumatoid arthritis, seronegative spondylo arthritis,Crohn's Disease, Ulcerative Colitis
MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 20.0;Classification code 10039073;Term: Rheumatoid arthritis;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 20.0;Classification code 10075634;Term: Acute haemorrhagic ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO
Product Name: Remsima
Product Code: 42942019
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLINULLNot RecruitingFemale: yes
Male: yes
250Phase 4Italy
2EUCTR2015-002284-42-FI
(EUCTR)
18/09/201528/08/2015The rationale for this study is to gain insight in the extent and impact of immunogenicityof TNF inhibitors in the European daily clinical practice. Furthermore, an European widedatabase will give insight in factors influencing immunogenicity and treatment outcomein terms of disease activitINTENT: immunogenicity in patients failing response on anti-TNF-Immunogenicity and pharmacokinetics in patients failing torespond to TNF inhibitors (phase 1);-Clinical effectiveness of subsequent TNF inhibitor treatment andpredictive value of pharmacokinetics and immunogenicity (phase2) - INTENT rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis.;Therapeutic area: Not possible to specifyTrade Name: Enbrel
Product Name: etanercept
Trade Name: Humira
Product Name: adalimumab
Trade Name: Cimzia
Product Name: certolizumab pegol
Trade Name: Simponi
Product Name: golimumab
Trade Name: Remicade
Product Name: infliximab
READENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
1650Phase 1Finland
3NCT02605642
(ClinicalTrials.gov)
September 10, 20152/9/2015Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From RemicadePERSIST: PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS PERSISTENCE OF CT-P13 (INFLIXIMAB) IN PATIENTS WITH RHEUMATOID DISEASES WHO ARE EITHER NAIVE TO BIOLOGICS OR SWITCHED FROM STABLE REMICADE(R) (INFLIXIMAB)Rheumatoid Diseases;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic ArthritisDrug: CT-P13PfizerHospira, now a wholly owned subsidiary of PfizerCompleted18 YearsN/AAll351Bulgaria;Canada;Czechia;Germany;Greece;Spain;United Kingdom;Czech Republic;France;Italy
4NCT02293681
(ClinicalTrials.gov)
April 10, 201514/11/2014An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip InvolvementA Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip InvolvementSpondylitis, AnkylosingDrug: Infliximab;Drug: NSAIDs;Drug: DMARDsJanssen Research & Development, LLCNULLTerminated16 Years40 YearsAll76N/AChina
5NCT02359903
(ClinicalTrials.gov)
February 201530/1/2015Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing SpondylitisInternational Multicenter Comparative Double Blind Study of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing SpondylitisAnkylosing SpondylitisDrug: Infliximab (BCD-055);Drug: Infliximab (Remicade)BiocadNULLCompleted18 Years65 YearsAll90Phase 1Belarus;Russian Federation
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2014-002056-40-NO
(EUCTR)
12/08/201413/06/2014A study to evaluate the safety and efficacy of switching from regular infliximab to biosimilar infliximab in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and psoriasisA RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN’S DISEASEAND CHRONIC PLAQUE PSORIASISTHE NOR-SWITCH STUDY - NOR_SWITCH Rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease and chronic plaque psoriasis
MedDRA version: 18.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 18.0;Level: LLT;Classification code 10071117;Term: Plaque psoriasis;System Organ Class: 100000004858
MedDRA version: 18.0;Classification code 10037160;Term: Psoriatic arthritis;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 18.0;Classification code 10045365;Term: Ulcerative colitis;Classification code 10002556;Term: Ankylosing spondylitis;Classification code 10071400;Term: Axial spondyloarthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Trade Name: Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital ASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Norway
7NCT02132234
(ClinicalTrials.gov)
June 201328/4/2014Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisEffects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisRheumatoid Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis;HypertensionDrug: Etanercept;Drug: Adalimumab;Drug: Certolizumab;Drug: InfliximabJagiellonian UniversityDepartmet of Rheumatology, J Dietl Hospital, Krakow, PolandRecruiting18 YearsN/ABoth100Phase 4Poland
8JPRN-UMIN000015297
2012/09/1901/10/2014The feasibility study of accelated infliximab infusion from initial administrationThe feasibility study of accelated infliximab infusion from initial administration - The feasibility study of accelated infliximab infusion from initial administration patient in whom infliximab is indicated(rheumatoid arthritis, Crohn's disease, Ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis)Administration of intravenous infliximab infusion with 60 min accelated procedure for patients who are already successfully treated with usual 2hr infuion without infusion reaction. The tolerable patient continue to receive more five treatment with 60min procedure.Chiba University HospitalNULLRecruiting20years-old70years-oldMale and Female54Phase 2Japan
9JPRN-UMIN000007806
2012/06/0101/05/2012The feasibility study of accelated infliximab infusion during maintenance phase patient in whom infliximab is indicated(rheumatoid arthritis, Crohn's disease, Ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis)Administration of intravenous infliximab infusion with 60 min accelated procedure for patients who are already successfully treated with usual 2hr infuion without infusion reaction. The tolerable patient continue to receive more five treatment with 60min procedure.Chiba University HospitalNULLComplete: follow-up completeNot applicableNot applicableMale and Female54Phase 2Japan
10NCT01610947
(ClinicalTrials.gov)
May 14, 201224/5/2012Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease ActivityEffect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity: a Randomized Controlled TrialSpondyloarthritisDrug: Adalimumab, Etanercept, Golimumab or infliximabUniversity Hospital, MontpellierNULLCompleted18 YearsN/AAll398N/AFrance
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01571206
(ClinicalTrials.gov)
March 201223/3/2012An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1Ankylosing SpondylitisBiological: InfliximabCelltrionNULLCompleted18 Years75 YearsBoth174Phase 1Korea, Republic of
12NCT01220518
(ClinicalTrials.gov)
October 20104/10/2010Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)Randomized, Double-blind, Parallel-group, Phase 1 StudyAnkylosing SpondylitisDrug: InfliximabCelltrionNULLCompleted18 Years75 YearsBoth257Phase 1Korea, Republic of
13NCT01148901
(ClinicalTrials.gov)
June 201021/6/2010Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)Hip Arthritis Associated With AS Efficacy and Safety of Early Treatment With Infliximab (Remicade®)Ankylosing SpondylitisDrug: InfliximabMerck Sharp & Dohme Corp.Hospital Universitario Reina Sofia;Dr. Jose María Martos Becerra (Central Radiological Assessment) – Hospital de Alta Resolución, Puente Genil (Spain)Withdrawn18 YearsN/ABoth0Phase 4Spain
14EUCTR2009-016587-36-ES
(EUCTR)
15/03/201027/01/2010Artritis de cadera asociada a la EA. Eficacia y Seguridad del tratamiento precoz con Infliximab (Remicade®)Artritis de cadera asociada a la EA. Eficacia y Seguridad del tratamiento precoz con Infliximab (Remicade®) Espondilitis anquilosante
MedDRA version: 12.1;Level: LLT;Classification code 10002556;Term: Ankylosing spondylitis
Trade Name: REMICADE 100 mg polvo para concentrado para solución para perfusión
INN or Proposed INN: INFLIXIMAB
Other descriptive name: INFLIXIMAB
Schering Plough, S.ANULLNot RecruitingFemale: yes
Male: yes
70Spain
15NCT00844805
(ClinicalTrials.gov)
September 200913/2/2009Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis TrialAnkylosing Spondylitis;Axial SpondyloarthritisDrug: Infliximab;Drug: Placebo;Drug: NaproxenMerck Sharp & Dohme Corp.NULLCompleted18 Years48 YearsAll158Phase 3Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2006-001579-40-DK
(EUCTR)
16/04/200804/09/2007Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab - EUSpAStudy of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab - EUSpA Spondyloarthropathies
MedDRA version: 9.1;Level: LLT;Classification code 10002556;Term: Ankylosing spondylitis
Trade Name: Remicade
INN or Proposed INN: infliximab
Schering-Plough FranceNULLNot RecruitingFemale: yes
Male: yes
120France;Hungary;Spain;Denmark
17NCT01072058
(ClinicalTrials.gov)
February 200818/2/2010Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF BlockerProspective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF BlockerArthritis, Rheumatoid;Spondylitis, AnkylosingDrug: TNF blockers (infliximab, adalimumab, etanercept)University of Sao PauloNULLActive, not recruiting18 Years70 YearsBoth100Phase 4Brazil
18NCT00936143
(ClinicalTrials.gov)
January 20087/7/2009Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing SpondylitisAn Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing SpondylitisSpondylitisDrug: infliximabGu JieruoNULLCompleted16 Years65 YearsBoth70Phase 4China
19EUCTR2006-001579-40-HU
(EUCTR)
18/12/200719/10/2007Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab - EUSpAStudy of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab - EUSpA Spondyloarthropathies
MedDRA version: 9.1;Level: LLT;Classification code 10002556;Term: Ankylosing spondylitis
Trade Name: Remicade
INN or Proposed INN: infliximab
Schering-Plough FranceNULLNot RecruitingFemale: yes
Male: yes
120Phase 4France;Hungary;Spain;Denmark
20NCT00507403
(ClinicalTrials.gov)
October 200724/7/2007Infliximab and Methotrexate in Ankylosing SpondylitisEffect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing SpondylitisAnkylosing SpondylitisDrug: infliximabUniversity Hospital, ToursInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted18 Years65 YearsAll30Phase 4France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21EUCTR2006-001579-40-ES
(EUCTR)
31/07/200704/05/2007Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximabESTUDIO DE LA ENTESITIS PERIFÉRICA CON ECOGRAFÍA DOPPLER EN LAS ESPONDILOARTROPATÍAS TRATADAS CON INFLIXIMAB - EUSpAStudy of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximabESTUDIO DE LA ENTESITIS PERIFÉRICA CON ECOGRAFÍA DOPPLER EN LAS ESPONDILOARTROPATÍAS TRATADAS CON INFLIXIMAB - EUSpA SpondyloarthropathiesEspondiloartropatias
MedDRA version: 9.1;Level: LLT;Classification code 10002556;Term: Ankylosing spondylitis
Trade Name: Remicade
INN or Proposed INN: infliximab
Schering-Plough FranceNULLNot RecruitingFemale: yes
Male: yes
100Hungary;Denmark;France;Spain
22NCT00724529
(ClinicalTrials.gov)
June 200725/7/2008Post Marketing Surveillance of RemicadePost Marketing Surveillance of Remicade in Inflammatory Bowel Disease (IBD)Crohn's Disease;Ankylosing SpondylitisBiological: InfliximabJanssen Korea, Ltd., KoreaNULLCompletedN/AN/ABoth938Korea, Republic of
23NCT00760669
(ClinicalTrials.gov)
May 200724/9/2008An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis ParticipantsPost Marketing Surveillance of Remicade in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis PatientsSpondylitis, Ankylosing;Arthritis, Rheumatoid;Psoriasis;Arthritis, PsoriaticDrug: Infliximab; observational study;Drug: MethotrexateJanssen Korea, Ltd., KoreaNULLCompletedN/AN/AAll1061Korea, Republic of
24EUCTR2006-005157-29-FR
(EUCTR)
27/04/200713/04/2007EFFET DU METHOTREXATE SUR LA RELATION DOSE - EFFET DE L'INFLIXIMAB DANS LA SPONDYLARTHRITE ANKYLOSANTE - SPAXIMEFFET DU METHOTREXATE SUR LA RELATION DOSE - EFFET DE L'INFLIXIMAB DANS LA SPONDYLARTHRITE ANKYLOSANTE - SPAXIM Les patients seront traités par infliximab, avec ou sans méthotrexate associé, selon la pratique habituelle en accord avec le libellé de l’A.M.M. Seuls le nombre de prélèvements sanguins et de visites diffèreront des modalités thérapeutiques habituelles.
MedDRA version: 9.1;Level: LLT;Classification code 10002556;Term: Ankylosing spondylitis
MedDRA version: 9.1;Level: SOC;Classification code 10028395;Term: Musculoskeletal and connective tissue disorders
Trade Name: Méthotrexate Bellon Comprimé
INN or Proposed INN: METHOTREXATE
Trade Name: REMICADE
INN or Proposed INN: INFLIXIMAB
CHRU-TOURSNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
25EUCTR2006-001579-40-FR
(EUCTR)
02/04/200726/03/2007Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab - EUSpAStudy of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab - EUSpA Spondyloarthropathies
MedDRA version: 9.1;Level: LLT;Classification code 10002556;Term: Ankylosing spondylitis
Schering-Plough FranceNULLNot Recruiting Female: yes
Male: yes
100Phase 4France;Hungary;Spain;Denmark
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2005-002460-29-BE
(EUCTR)
17/02/200608/02/2006An Open Extension, Investigator Initiated Trial, to Examine Radiographic progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC: (European Ankylosing Spondylitis Infliximab Cohort) - EASICAn Open Extension, Investigator Initiated Trial, to Examine Radiographic progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC: (European Ankylosing Spondylitis Infliximab Cohort) - EASIC Ankylosing spondylitis (AS)Product Name: Remicade
Product Code: cA2
INN or Proposed INN: Infliximab
Other descriptive name: Anti-(human tumor necrosis factor) immunoglobulin G (human-mouse monoclonal cA2 heavy chain)
Rheumazentrum Ruhrgebiet.NULLNot RecruitingFemale: yes
Male: yes
130Phase 4Finland;Belgium;Germany;United Kingdom
27EUCTR2005-002460-29-FI
(EUCTR)
20/01/200612/12/2005An Open Label Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC: (European Ankylosing Spondylitis Infliximab Cohort) - EASICAn Open Label Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC: (European Ankylosing Spondylitis Infliximab Cohort) - EASIC Ankylosing spondylitis (AS)Product Name: Remicade
Product Code: cA2
INN or Proposed INN: Infliximab
Other descriptive name: Anti-(human tumor necrosis factor) immunoglobulin G (human-mouse monoclonal cA2 heavy chain)
Rheumazentrum Ruhrgebiet.NULLNot RecruitingFemale: yes
Male: yes
130Finland;United Kingdom;Germany;Belgium
28EUCTR2005-002460-29-GB
(EUCTR)
22/12/200503/10/2005 An Open Label Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC: (European Ankylosing Spondylitis Infliximab Cohort) - EASIC An Open Label Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC: (European Ankylosing Spondylitis Infliximab Cohort) - EASIC Ankylosing spondylitis (AS)Rheumazentrum Ruhrgebiet.NULLNot Recruiting Female: yes
Male: yes
130Phase 4Finland;Belgium;Germany;United Kingdom
29NCT00237419
(ClinicalTrials.gov)
December 200510/10/2005Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing SpondylitisAn Open Label Extension, Investigator Initiated Trial to Examine Radiographic Progression , Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis. EASIC (European Ankylosing Spondylitis Infliximab Cohort)Ankylosing SpondylitisDrug: infliximabRheumazentrum RuhrgebietCentocor BV;Trial Coordination Center, 9713 GZ Groningen;PPDRecruiting18 YearsN/ABoth149N/ABelgium;Finland;France;Germany;Netherlands;United Kingdom
30EUCTR2005-002460-29-DE
(EUCTR)
12/09/200505/07/2005An Open Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC (European Ankylosing Spondylitis Infliximab Cohort) - EASICAn Open Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC (European Ankylosing Spondylitis Infliximab Cohort) - EASIC Ankylosing spondylitis (AS)Product Name: Remicade
Product Code: cA2
INN or Proposed INN: Infliximab
Other descriptive name: Anti-(human tumor necrosis factor) immunoglobulin G (human-mouse monoclonal cA2 heavy chain)
Rheumazentrum Ruhrgebiet.NULLNot RecruitingFemale: yes
Male: yes
130Finland;United Kingdom;Germany;Belgium
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT00778869
(ClinicalTrials.gov)
August 200523/10/2008Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy ControlsSpondylitis, AnkylosingBiological: RemicadeMerck Sharp & Dohme Corp.NULLCompleted18 Years70 YearsAll10Phase 4NULL
32NCT00202865
(ClinicalTrials.gov)
May 1, 200516/9/2005Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)CANaDian Evaluation of Low DosE Infliximab in Ankylosing SpondylitisSpondylitis, AnkylosingBiological: infliximab;Biological: PlaceboMerck Sharp & Dohme Corp.NULLCompleted18 YearsN/AAll76Phase 3Canada
33NCT00432432
(ClinicalTrials.gov)
February 20056/2/2007Combination Methotrexate and InfliximabThe Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging CorrelationAnkylosing SpondylitisDrug: Infliximab and MTXChinese University of Hong KongNULLCompleted18 Years70 YearsBoth38Phase 4NULL
34NCT00779935
(ClinicalTrials.gov)
October 1, 200423/10/2008Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot StudySpondylitis, AnkylosingBiological: RemicadeMerck Sharp & Dohme Corp.NULLCompleted18 Years70 YearsAll44Phase 4NULL
35NCT00779012
(ClinicalTrials.gov)
October 1, 200423/10/2008A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing SpondylitisSpondylitis, AnkylosingBiological: InfliximabMerck Sharp & Dohme Corp.NULLCompleted18 Years70 YearsAll42Phase 4NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT00133315
(ClinicalTrials.gov)
September 200422/8/2005TNFalfa Blocking Treatment of SpondylarthropathiesTNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With SpondylarthropathiesSpondylarthropathies;Ankylosing Spondylitis;Psoriatic ArthritisDrug: Infliximab;Drug: Etanercept;Drug: AdalimumabHvidovre University HospitalNULLCompleted18 YearsN/ABoth50Phase 4Denmark
37NCT00725543
(ClinicalTrials.gov)
June 200425/7/2008Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)Remicade Therapy in Ankylosing Spondylitis: Investigation of Real Life Regimen in Austria Over 9 Consecutive InfusionsSpondylitis, AnkylosingBiological: InfliximabMerck Sharp & Dohme Corp.Centocor, Inc.CompletedN/AN/AAll358N/ANULL
38NCT00818168
(ClinicalTrials.gov)
July 20036/1/2009Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)Remicade Safety Line (Ankylosing Spondylitis)Spondylitis, AnkylosingBiological: InfliximabMerck Sharp & Dohme Corp.Centocor, Inc.Completed18 YearsN/AAll320N/AGermany
39NCT00439283
(ClinicalTrials.gov)
April 200322/2/2007Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing SpondylitisStudy of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis: Comparison of Infusion Every 6 Weeks Versus Infusion on DemandAnkylosing SpondylitisDrug: infliximab;Drug: methotrexateAssociation de Recherche Clinique en RhumatologieNULLCompleted18 YearsN/ABoth240Phase 3France
40NCT01850121
(ClinicalTrials.gov)
January 20036/5/2013Remicade in the Treatment of Patients With Active Ankylosing SpondylitisRemicade in the Treatment of Patients With Active Ankylosing SpondylitisAnkylosing SpondylitisDrug: InfliximabGöteborg UniversityNULLCompleted18 Years60 YearsBoth19Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT00207701
(ClinicalTrials.gov)
September 200213/9/2005A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug TherapyAnkylosing SpondylitisDrug: infliximabCentocor, Inc.Centocor BV, NetherlandsCompleted18 YearsN/ABoth279Phase 3NULL
42JPRN-JapicCTI-070346
22/01/2007Clinical study of TA-650 in patients with ankylosing spondylitisClinical study of TA-650 in patients with ankylosing spondylitis Ankylosing spondylitisIntervention name : TA-650 (Infliximab)
Dosage And administration of the intervention : Intravenous drip infusion
Mitsubishi Tanabe Pharma CorporationNULL16BOTHPhase 3NULL